PARP1 is required for the maintenance of MLL-AF9 leukemias.PARP1 inhibitors enhance the therapeutic effect of cytotoxic drugs against MLL-AF9 leukemias.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728460 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2017006247 | DOI Listing |
Publication Analysis
Top Keywords
mll-af9 leukemias
8
cytotoxic drugs
8
leukemias sensitive
4
sensitive parp1
4
parp1 inhibitors
4
inhibitors combined
4
combined cytotoxic
4
drugs parp1
4
parp1 required
4
required maintenance
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!